DAY 1 - APRIL 20, 2022 (ALL TIMES PDT)
** Schedule Subject to Change **
Registration & Networking
Breakfast
Poster Sessions - All Day
1:1 Meetings - All Day
Welcome - Marc Cummings, Life Science Washington CEO
What It Takes To Translate New Modalities into FDA Approvals
New modalities are coming of age with increasing FDA approvals for Antibody-drug conjugates, cell and gene therapies, DNA and RNA therapies, and bispecific antibodies. Hear from experts who have steered these therapies through approval and the lessons they have learned.
Poster/Device Showcase
Company/Research Institution Presentations
To view the Company Presentations for this session, please visit the Presentation Schedule.
Lunch
Capital Markets Outlook and Strategies for Building Financially Stable Life Science Companies in Dynamic Times
2021 was a banner year for Washington’s life science sector with a record number of IPOs and near historic levels of investment. However, there have also been large market fluctuations with the biotech market index down considerably and many newly minted public companies seeing depressed valuations. What’s the market outlook for publicly traded companies? Can younger companies access capital and grow organically or will more traditional licensing, partnerships, and acquisitions with major pharma become the norm? This panel will hear from a variety of financial deal experts representing different stages of maturity. They will explore how best to raise capital and position themselves for growth in the coming years.
Panelists
Poster/Device Showcase
Company/Research Institution Presentations
To view the Company Presentations for this session, please visit the Presentation Schedule.
An Industry Legends Interview - Story of Seagen: From Regional Startup to Global, Industry-Leading Company
Join us for an exciting interview between industry legends Clay Siegall, PhD, President & CEO, Seagen, and moderator Steve Harr, MD, President & CEO, Sana Biotechnology, and 2022 LSINW Program Chair, as they discuss what it takes to bring a company from a regional startup to a global, industry-leading company.
Fast Pitch Showdown
Move over Shark Tank! Twelve life science early-stage companies compete for a $5,000 judges-pick prize. Judges Alice Ly from Alexandria Venture Investments, Chris Picardo from Madrona Venture Group, Rachel Rath from Johnson & Johnson Innovation, and Sacha Mann from Takeda Ventures will decide which 60 second pitch drives the best business opportunity. Past winners include current rising stars Axolotl, Tasso, A-Alpha Bio, and Nanodropper.
Industry Reception
DAY 2 - APRIL 21, 2022 (ALL TIMES PDT)
Registration & Networking
Breakfast
Poster Sessions - All Day
1:1 Meetings - All Day
Welcome - Rich Fabian, President & COO, FUJIFILM SonoSite, Life Science Washington Board Chair
Keynote Speaker
Turning New Technologies into Medicines
The new product pipeline is exploding with over 1,200 experimental therapies, many in new modalities such as DNA editing, RNA editing, and bi-specific antibodies. What hurdles must they overcome to translate into clinical trials? How will they be manufactured? How can they be paired with existing treatments?
Stay tuned for additional panelist announcements.
Panelists
Break
Company/Research Institution Presentations
To view the Company Presentations for this session, please visit the Presentation Schedule.
Lunch
Conversation with new Life Science Washington CEO, Marc Cummings
Federal Policy Update from Rep DelBene
Panelists
Next Frontier for Cell Therapies and Autoimmune Disorders
T cells, specifically regulatory T cells (Tregs), are key immune cells that function to suppress the overactivity of other immune cells. Innovations in identifying, characterizing, stabilizing, and editing Tregs make them attractive candidates to advance as next-generation therapies to treat autoimmune conditions, HIV infections, and cancers. Hear from experts who lead these promising therapies while breaking barriers to address potential challenges that lie ahead.
Stay tuned for additional panelist announcements.